Advertisement

Osteoporosis International

, Volume 30, Issue 2, pp 461–468 | Cite as

Health-related quality of life in children with osteogenesis imperfecta: a large-sample study

  • Y. Song
  • D. Zhao
  • L. Li
  • F. Lv
  • O. Wang
  • Y. Jiang
  • W. Xia
  • X. Xing
  • M. LiEmail author
ORIGINAL ARTICLE

Abstract

Summary

In this large-sample study, we demonstrated that osteogenesis imperfecta (OI) significantly impaired the quality of life (QoL) in children. Moderate/severe OI patients had worse QoL scores than patients with mild OI. Furthermore, the QoL for OI patients was correlated with the presence of pathogenic gene mutations.

Introduction

Osteogenesis imperfecta (OI) is a hereditary disease characterized by multiple fragility fractures and progressive skeletal deformities. No detailed investigations about the quality of life (QoL) have been carried out in a large sample of patients with OI. We evaluated the QoL and its influencing factors in a large and well-characterized OI cohort.

Methods

We used a validated questionnaire of PedsQL 4.0 to evaluate the health-related quality of life (HRQoL) of children and adolescents with OI. We compared HRQoL among patients with OI types I, III, and IV. The relationship between HRQoL and pathogenic mutations in candidate OI genes was investigated. We also evaluated the influencing factors of HRQoL in OI patients.

Results

A total of 138 children with OI and 138 healthy controls were enrolled in this study. The HRQoL scores of OI patients were 64.4 ± 30.0, 71.9 ± 22.2, 75.7 ± 24.8, 63.7 ± 24.5, and 68.9 ± 22.0 in physical, emotional, social, school functioning, and total score, respectively, which were significantly lower than those of healthy children (86.5 ± 12.7, 83.3 ± 16.0, 92.1 ± 11.8, 87.5 ± 11.8, and 87.3 ± 10.7, all p < 0.01). Moderate and severe OI (type III/IV) patients had poorer HRQoL scores than patients with mild OI (type I). Gene mutations inducing qualitative defects in type I collagen led to worse HRQoL scores than those with quantitative defects in type I collagen, except in emotional functioning. The total HRQoL score was positively correlated with family income, lumbar, and femoral bone mineral density (BMD) Z-scores and negatively correlated with disease severity and fracture frequency.

Conclusion

HRQoL was significantly impaired in OI patients, and patients with more severe OI had poorer HRQoL scores. For the first time, we found that children with qualitative defects in type I collagen had poorer HRQoL scores than those with quantitative defects in type I collagen.

Keywords

Health-related quality of life Osteogenesis imperfecta Pathogenic mutations PedsQL 4.0 

Notes

Acknowledgments

We thank the staff in the radiology department for measurement of the bone mineral density and interpretation of X-ray films of bone. We also thank the patients with OI and healthy children for completing the questionnaires.

Funding information

This study was supported by National Natural Science Foundation of China (No. 81570802), the National Key Research and Development Program of China (No. 2016YFC0901501), and CAMS Initiative for Innovative Medicine (2016-I2M-3-003).

Compliance with ethical standards

The study was approved by the scientific ethics committee of Peking Union Medical College Hospital.

Conflicts of interest

None.

Supplementary material

198_2018_4801_MOESM1_ESM.pptx (102 kb)
ESM 1 (PPTX 102 kb)
198_2018_4801_MOESM2_ESM.docx (44 kb)
ESM 2 (DOCX 43.5 kb)

References

  1. 1.
    Marini JC, Forlino A, Bächinger HP, Bishop NJ, Byers PH, Paepe A, Fassier F, Fratzl-Zelman N, Kozloff KM, Krakow D, Montpetit K, Semler O (2017) Osteogenesis imperfecta. Nat Rev Dis Primers 3:17052CrossRefGoogle Scholar
  2. 2.
    Lim J, Grafe I, Alexander S, Lee B (2017) Genetic causes and mechanisms of osteogenesis imperfecta. Bone 102:40–49CrossRefGoogle Scholar
  3. 3.
    Marini JC, Reich A, Smith SM (2014) Osteogenesis imperfecta due to mutations in non-collagenous genes. Curr Opin Pediatr 26(4):500–507CrossRefGoogle Scholar
  4. 4.
    Song Y, Zhao D, Xu X, Lv F, Li L, Jiang Y, Wang O, Xia W, Xing X, Li M (2018) Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X. Osteoporos Int 29(6):1389–1396CrossRefGoogle Scholar
  5. 5.
    Xu XJ, Lv F, Liu Y, Wang JY, Ma DD, Asan WJW, Song LJ, Jiang Y, Wang O, Xia WB, Xing XP, Li M (2017) Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid. J Hum Genet 62(2):205–211CrossRefGoogle Scholar
  6. 6.
    Barbirato C, Trancozo M, Rebouças MR, Sipolatti V, Nunes VR, Paula F. (2016) Analysis of FKBP10, SERPINH1, and SERPINF1 genes in patients with osteogenesis imperfecta. Genet Mol Res 15(3): gmr.15038665Google Scholar
  7. 7.
    Eyre DR, Weis MA (2013) Bone collagen: new clues to its mineralization mechanism from recessive osteogenesis imperfecta. Calcif Tissue Int 93(4):338–347CrossRefGoogle Scholar
  8. 8.
    Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101–116CrossRefGoogle Scholar
  9. 9.
    Bradbury LA, Barlow S, Geoghegan F, Hannon RA, Stuckey SL, Wass JA, Russell RG, Brown MA, Duncan EL (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporosis Int 23:285–294CrossRefGoogle Scholar
  10. 10.
    Khadilkar AV, Sanwalka NJ, Chiplonkar SA, Khadilkar VV, Mughal MZ (2011) Normative data and percentile curves for dual energy X-ray absorptiometry in healthy Indian girls and boys aged 5-17 years. Bone 48(4):810–819CrossRefGoogle Scholar
  11. 11.
    Liu Y, Asan MD, Lv F, Xu X, Wang J, Xia W, Jiang Y, Wang O, Xing X, Yu W, Wang J, Sun J, Song L, Zhu Y, Yang H, Wang J, Li M (2017) Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing. Osteoporos Int 28(10):2985–2995CrossRefGoogle Scholar
  12. 12.
    Lv F, Xu X, Song Y, Li L, Asan WJ, Yang H, Wang O, Jiang Y, Xia W, Xing X, Li M (2018) Novel mutations in PLOD2 cause rare Bruck syndrome. Calcif Tissue Int 102(3):296–309CrossRefGoogle Scholar
  13. 13.
    Wang JY, Liu Y, Song LJ, Lv F, Xu XJ, San A, Wang J, Yang HM, Yang ZY, Jiang Y, Wang O, Xia WB, Xing XP, Li M (2017) Novel mutations in SERPINF1 result in rare osteogenesis imperfecta type VI. Calcif Tissue Int 100(1):55–66CrossRefGoogle Scholar
  14. 14.
    Liu Y, Wang J, Ma D, Lv F, Xu X, Xia W, Jiang Y, Wang O, Xing X, Zhou P, Wang J, Yu W, ASAN LM (2016) Osteogenesis imperfecta type V: genetic and clinical findings in eleven Chinese patients. Clin Chim Acta 462:201–209CrossRefGoogle Scholar
  15. 15.
    Dogba MJ, Bedos C, Durigova M, Montpetit K, Wong T, Glorieux FH, Rauch F (2013) The impact of severe osteogenesis imperfecta on the lives of young patients and their parents—a qualitative analysis. BMC Pediatr 13:153CrossRefGoogle Scholar
  16. 16.
    Edwards TC, Patrick DL, Topolski TD (2003) Quality of life of adolescents with perceived disabilities. J Pediatr Psychol 28:233–241CrossRefGoogle Scholar
  17. 17.
    Engelbert RH, Uiterwaal CS, Gerver WJ, van der Net JJ, Pruijs HE, Helders PJ (2004) Osteogenesis imperfecta in childhood: impairment and disability. A prospective study with 4-year follow-up. Arch Phys Med Rehab 85:772–778Google Scholar
  18. 18.
    Hill CL, Baird WO, Walters SJ (2014) Quality of life in children and adolescents with osteogenesis imperfecta: a qualitative interview based study. Health Qual Life Outcomes 2014; 12:54Google Scholar
  19. 19.
    Fano V, del Pino M, Rodríguez Celin M, Buceta S, Obregón MG (2013) Osteogenesis imperfecta: quality of life in children. Arch Argent Pediatr 111(4):328–331CrossRefGoogle Scholar
  20. 20.
    Vanz AP, van de Sande Lee J, Pinheiro B, Zambrano M, Brizola E, da Rocha NS, Schwartz IVD, de Souza Pires MM, Félix TM (2018) Health-related quality of life of children and adolescents with osteogenesis imperfecta: a cross-sectional study using PedsQL™. BMC Pediatr 18(1):95CrossRefGoogle Scholar
  21. 21.
    Dahan-Oliel N, Oliel S, Tsimicalis A (2016) Quality of life in osteogenesis imperfecta: a mixed-methods systematic review. Am J Med Genet A 170A(1):62–76CrossRefGoogle Scholar
  22. 22.
    Engelbert RH, Custers JW, van der Net J (1997) Functional outcome in osteogenesis imperfecta: disability profiles using the PEDI. Pediatr Phys Ther 9(1):18–22CrossRefGoogle Scholar
  23. 23.
    Engelbert RH, van der Graaf Y, van Empelen R, Beemer FA, Helders PJ (1997) Osteogenesis imperfecta in childhood: impairment and disability. Pediatrics 99(2):E3CrossRefGoogle Scholar
  24. 24.
    Montpetit K, Dahan-Oliel N, Ruck-Gibis J, Fassier F, Rauch F, Glorieux F (2011) Activities and participation in young adults with osteogenesis imperfecta [comparative study]. J Pediatr Rehabil Med 4(1):13–22Google Scholar
  25. 25.
    Sousa T, Bompadre V, White KK (2014) Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. J Pediatr Orthop 34(1):118–122CrossRefGoogle Scholar
  26. 26.
    Tsimicalis A, Denis-Larocque G, Michalovic A, Lepage C, Williams K, Yao TR, Palomo T, Dahan-Oliel N, Le May S, Rauch F (2016) The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review. Qual Life Res 25:1877–1896CrossRefGoogle Scholar
  27. 27.
    Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Söderhäll S, Ljunggren Ö, Åström E (2016) Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Bone 87:11–18CrossRefGoogle Scholar
  28. 28.
    Dwan K, Phillipi CA, Steiner RD, Basel D (2014) Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev D5088Google Scholar
  29. 29.
    Marginean O, Tamasanu RC, Mang N, Mozos I, Brad GF (2017) Therapy with pamidronate in children with osteogenesis imperfecta. Drug Des Devel Ther 11:2507–2515CrossRefGoogle Scholar
  30. 30.
    Tsimicalis A, Boitor M, Ferland CE, Rauch F, Le May S, Carrier JI, Ngheim T, Bilodeau C (2018) Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle. Eur J Pediatr 177(6):891–902CrossRefGoogle Scholar
  31. 31.
    Hoyer-Kuhn H, Stark C, Franklin J, Schoenau E, Semler O (2017) Correlation of bone mineral density on quality of life in patients with osteogenesis imperfecta during treatment with denosumab. Pediatr Endocrinol Rev 15(Suppl 1):123–129Google Scholar
  32. 32.
    Feehan AG, Zacharin MR, Lim AS, Simm PJ (2018) A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood. Bone 113:137–143CrossRefGoogle Scholar
  33. 33.
    Lin HY, Chuang CK, Su YN, Chen MR, Chiu HC, Niu DM, Lin SP (2015) Genotype and phenotype analysis of Taiwanese patients with osteogenesis imperfecta. Orphanet J Rare Dis 10:152CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2018

Authors and Affiliations

  • Y. Song
    • 1
    • 2
  • D. Zhao
    • 1
  • L. Li
    • 1
  • F. Lv
    • 1
  • O. Wang
    • 1
  • Y. Jiang
    • 1
  • W. Xia
    • 1
  • X. Xing
    • 1
  • M. Li
    • 1
    Email author
  1. 1.Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, National Health and Family Planning Commission, Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina
  2. 2.Department of EndocrinologyThe Second Hospital of Shandong UniversityJinanChina

Personalised recommendations